(
Important patent secured in the US for PreciseInhale[®]
Today's standard technologies for scientists, helping them measure how inhaled particles act in our lungs and affect our health, are imprecise and largely unchanged since the 1950's. PreciseInhale[®] sets a completely new standard as it delivers results with a proven high correlation between laboratory in vitro testing, and animal exposure, and soon also to human testing - enabling more cost-efficient medicines for a large variety of accelerating global killer diseases of the respiratory tract.
Inhalation Sciences now reports that the US patent office has issued a notice on
CEO Manoush Masarrat: "This new patent is of vital strategic importance for us. Following our recently approved new patent for `regional targeting' (https://inhalation.se/investors/pressmeddelanden/?pressreleaseId=3706611), it is yet further proof of how we continue to be the leading innovators in aerosol and inhalation R&D, a fast-growing and ever more urgent market."
Lucrative market opportunities
The global respiratory care devices market is expected to grow from
*Fior Markets report 417943 on Medical Devices
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush Masarrat@inhalation.se
Telephone: +46 (0)736 289 153
About
Inhalation Sciences develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.
Inhalation Sciences shares are traded on the
https://news.cision.com/inhalation-sciences/r/inhalation-sciences-secures-important-ip-rights,c3227712
https://mb.cision.com/Main/15842/3227712/1327720.pdf
(c) 2020 Cision. All rights reserved., source